MedWatch

Saniona fails in eating disorder study - tries again with higher doses

Although Saniona's Tesomet was well-tolerated in a phase IIa trial with young Prader-Willi patients, the drug did not have the desired effect. The Danish company is now awaiting permission to prolong the study with a higher dose.

Foto: Saniona/ PR

There were smiles all over at Saniona in January, when the company completed a phase IIa trial with the drug Tesomet in teenage patients with the rare eating disorder Prader-Willi Syndrome.

The drug was well-tolerated, and Saniona prepared for extension studies in Hungary and Czech Republic. But when the final data arrived, they put a damper on the optimism.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier